A detailed history of Avenir Corp transactions in Cytosorbents Corp stock. As of the latest transaction made, Avenir Corp holds 2,970,262 shares of CTSO stock, worth $4.01 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
2,970,262
Previous 3,172,696 6.38%
Holding current value
$4.01 Million
Previous $3.01 Million 31.02%
% of portfolio
0.21%
Previous 0.27%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.7 - $1.01 $141,703 - $204,458
-202,434 Reduced 6.38%
2,970,262 $2.08 Million
Q1 2024

May 15, 2024

BUY
$0.86 - $1.07 $104,312 - $129,784
121,294 Added 3.98%
3,172,696 $3.01 Million
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.94 $360,725 - $647,969
334,005 Added 12.29%
3,051,402 $3.39 Million
Q3 2023

Nov 14, 2023

SELL
$1.86 - $4.03 $4,343 - $9,410
-2,335 Reduced 0.09%
2,717,397 $5.11 Million
Q2 2023

Aug 11, 2023

BUY
$2.37 - $3.65 $389,104 - $599,253
164,179 Added 6.42%
2,719,732 $9.76 Million
Q1 2023

May 15, 2023

BUY
$1.79 - $4.17 $194,150 - $452,294
108,464 Added 4.43%
2,555,553 $8.61 Million
Q4 2022

Feb 14, 2023

BUY
$1.03 - $2.03 $136,202 - $268,437
132,235 Added 5.71%
2,447,089 $3.79 Million
Q3 2022

Nov 14, 2022

BUY
$1.2 - $2.46 $179,826 - $368,643
149,855 Added 6.92%
2,314,854 $3.15 Million
Q2 2022

Aug 11, 2022

SELL
$1.76 - $3.22 $20,257 - $37,062
-11,510 Reduced 0.53%
2,164,999 $4.74 Million
Q1 2022

May 16, 2022

BUY
$2.88 - $4.23 $1.12 Million - $1.65 Million
389,234 Added 21.78%
2,176,509 $6.94 Million
Q4 2021

Feb 16, 2022

BUY
$4.05 - $8.11 $1.59 Million - $3.18 Million
391,890 Added 28.08%
1,787,275 $7.49 Million
Q3 2021

Nov 12, 2021

BUY
$7.0 - $9.71 $201,852 - $279,997
28,836 Added 2.11%
1,395,385 $11.3 Million
Q2 2021

Aug 13, 2021

BUY
$7.55 - $9.42 $7.61 Million - $9.49 Million
1,007,679 Added 280.79%
1,366,549 $10.3 Million
Q1 2021

May 14, 2021

BUY
$8.23 - $11.48 $1.25 Million - $1.75 Million
152,130 Added 73.59%
358,870 $3.12 Million
Q4 2020

Feb 12, 2021

BUY
$7.65 - $8.98 $126,225 - $148,170
16,500 Added 8.67%
206,740 $1.65 Million
Q3 2020

Nov 13, 2020

BUY
$7.37 - $11.54 $165,972 - $259,880
22,520 Added 13.43%
190,240 $1.52 Million
Q2 2020

Aug 14, 2020

BUY
$6.28 - $10.59 $107,513 - $181,300
17,120 Added 11.37%
167,720 $1.66 Million
Q3 2019

Nov 13, 2019

BUY
$4.33 - $7.63 $22,949 - $40,439
5,300 Added 3.65%
150,600 $758,000
Q2 2019

Aug 12, 2019

BUY
$5.92 - $7.78 $343,715 - $451,706
58,060 Added 66.55%
145,300 $960,000
Q1 2019

May 14, 2019

BUY
$6.82 - $8.56 $73,997 - $92,876
10,850 Added 14.2%
87,240 $660,000
Q4 2018

Feb 13, 2019

BUY
$7.05 - $12.64 $240,651 - $431,466
34,135 Added 80.78%
76,390 $617,000
Q3 2018

Nov 14, 2018

BUY
$10.95 - $14.8 $122,475 - $165,538
11,185 Added 36.0%
42,255 $545,000
Q2 2018

Aug 14, 2018

BUY
$6.9 - $12.35 $214,383 - $383,714
31,070 New
31,070 $354,000

Others Institutions Holding CTSO

About Cytosorbents Corp


  • Ticker CTSO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 43,577,400
  • Market Cap $58.8M
  • Description
  • Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...
More about CTSO
Track This Portfolio

Track Avenir Corp Portfolio

Follow Avenir Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avenir Corp, based on Form 13F filings with the SEC.

News

Stay updated on Avenir Corp with notifications on news.